

IN THE CLAIMS:

The following is a listing of the claims currently pending in the above-identified application. This listing replaces all prior listings and versions of the claims. Any deletion of subject matter from the claims or any cancellation of claims is effected without prejudice.

1.-5. (Cancelled)

6. (Currently Amended) A ~~pharmaceutical~~ composition comprising (a) an amount of phanquinone and a compound, or a mixture of compounds, selected from the group comprising antioxidants, acetylcholine enhancers, trace metals, prosthetic groups and clioquinol provided, when clioquinol is selected, that at least one further compound is selected from the said group effective to treat Alzheimer's disease and (b) a mixture of clioquinol, vitamin B₁₂ and an acetylcholine enhancer.

7.-42. (Cancelled)

43. (Currently Amended) The ~~pharmaceutical~~ composition according to claim ~~[[42]]~~ 6, wherein the total amount of the compounds in (b) is sufficient for increasing the effect of the treatment of Alzheimer's disease or for inhibiting any detrimental side effect.

44. (Currently Amended) The ~~pharmaceutical~~ composition according to claim ~~[[42]]~~ 6, wherein the ~~amount of (b) the compound(s) is~~ mixture is present in an amount ranging from 5µg to 250 mg.

45. (Currently Amended) The ~~pharmaceutical~~ composition according to claim ~~[[42]]~~ 6, wherein ~~[[the]]~~ an antioxidant ~~[[is]]~~ selected from the group ~~comprising~~ consisting of vitamin C, vitamin E, and Q10, or combinations thereof is additionally present.

46. (Currently Amended) The ~~pharmaceutical~~ composition according to claim ~~[[42]]~~ 6, wherein the acetylcholine enhancer is tacrine.

47. (Currently Amended) The ~~pharmaceutical~~ composition according to claim ~~[[42]]~~ 6, wherein the acetylcholine enhancer is donepezil.

48.-49. (Cancelled)

50. (Currently Amended) The ~~pharmaceutical~~ composition according to ~~any of the claims 42 or 49~~ claim 6, which further comprises a pharmaceutical acceptable carrier.

51. (Currently Amended) The ~~pharmaceutical~~ composition according to ~~any of the claims 42 or 49~~ claim 6, wherein the amount of phanquinone is 5 mg to 250 mg.

52. (Currently Amended) The ~~pharmaceutical~~ composition according to ~~any of the claims 42 or 49~~ claim 6, wherein the amount of phanquinone is 10 mg to 50 mg.

53. (Currently Amended) The ~~pharmaceutical~~ composition according to claim ~~[[49]]~~ 6, comprising an amount of clioquinol effective to improve the treatment ~~or prevention~~ of Alzheimer's disease.

54. (Currently Amended) The ~~pharmaceutical~~ composition according to claim ~~[[49]]~~ 6, comprising an amount of vitamin B₁₂ effective to inhibit a detrimental side effect of clioquinol administration.

55. (Currently Amended) The ~~pharmaceutical~~ composition according to claim ~~[[49]]~~ 6, wherein the amount of clioquinol is 5 mg to 250 mg.

56. (Currently Amended) The ~~pharmaceutical~~ composition according to claim ~~[[49]]~~ 6, wherein the amount of clioquinol is 10 mg to 50 mg.

57. (Currently Amended) The ~~pharmaceutical~~ composition according to claim ~~[[49]]~~ 6, wherein the amount of vitamin B₁₂ is 5 μ g to 2 mg.

58. (Currently Amended) The ~~pharmaceutical~~ composition according to claim ~~[[49]] 6~~, wherein the amount of vitamin B₁₂ is 0.5 mg to 1 mg.
59. (Currently Amended) The ~~pharmaceutical~~ composition according to claim ~~42 or 49 6~~, wherein the composition is formulated for parenteral administration.
60. (Currently Amended) The ~~pharmaceutical~~ composition according to claim ~~42 or 49 6~~, wherein the composition is formulated for intradermal administration.
61. (Currently Amended) The ~~pharmaceutical~~ composition according to claim ~~42 or 49 6~~, wherein the composition is formulated for oral administration.
62. (Currently Amended) The ~~pharmaceutical~~ composition according to claim ~~42 or 49 6~~, wherein the composition is formulated as a tablet.
63. (Currently Amended) The ~~pharmaceutical~~ composition according to claim ~~[[49]] 6~~, wherein the clioquinol and vitamin B₁₂ are formulated in separate pharmaceutical entities, phanquinone being formulated together with clioquinol, vitamin B₁₂, or separate.
64. (Withdrawn) A kit comprising in one or more containers an amount of phanquinone and clioquinol effective to treat or prevent Alzheimer's disease, and an amount of vitamin B₁₂ effective to inhibit a detrimental side effect of clioquinol administration.